RCT: Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling.

Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter

RCT: 10 to 25 mg/day agomelatine resulted in an improvement versus placebo in CDRS-R raw score of 4·22 (0·63–7·82) at 12 weeks in C&A with MDD, with a similar effect for fluoxetine. The overall effect was confirmed in adolescents, but not in children https://t.co/keecz57fQw

— PfOL (@psychopharmacol) December 23, 2021